1 / 36

16 February 2005

FDA Advisory Committee Meeting. 16 February 2005. Cardiovascular Safety of Valdecoxib and Parecoxib & Risk-Benefit Assessment. Valdecoxib - Background. Valdecoxib approved for OA and RA in Nov ‘01 Approved dose = 10 mg once daily

ephraim
Download Presentation

16 February 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FDA Advisory Committee Meeting 16 February 2005 Cardiovascular Safety of Valdecoxib and Parecoxib & Risk-Benefit Assessment

  2. Valdecoxib - Background • Valdecoxib approved for OA and RA in Nov ‘01 • Approved dose = 10 mg once daily • >15,000 individuals studied in the registration program = celecoxib • Since the approval: • Acute pain and chronic pain conditions

  3. Valdecoxib Overall Conclusions • Valdecoxib remains a viable treatment alternative for OA and RA • Valdecoxib provides improved GI safety compared to NSAIDs • Valdecoxib CV safety database is small at present, however, emerging CV safety profile of valdecoxib is similar to NSAIDs for up to 6 months. • CV signal in CABG surgery setting does not extrapolate to the arthritis population.

  4. Clinical Effects of Valdecoxib in OA Efficacy Upper GI Safety B H 11 Placebo (n=205) 20 F B J P J Valdecoxib 5 mg QD (n=201) H Valdecoxib 10 mg QD (n=205) 10 15 F Valdecoxib 20 mg QD (n=201) P Naproxen 500 mg BID (n=204) Patients with Ulcer (%) WOMAC Pain Scorea 9 * B ** 10 † B ‡ B 8 J H P H F H 5 J J P F P F 7 0 0 0 2 6 12 Pbo 5 10 20 500 Weeks Valdecoxib (mg qd) Naproxen (mg bid) a. Scale = 0 (best) - 20 (worst) * Placebo significantly different from all treatments; p < 0.05 † Placebo significantly different from all treatments except valdecoxib 5 mg; p < 0.05 ‡ Placebo significantly different from valdecoxib 20 mg and naproxen; p < 0.05 ** Significantly different from placebo, valdecoxib 5 mg and 10 mg; p < 0.05 Kivitz et al. J Family Practice 2002:51;530-537

  5. Incidence of Ulcer Complications Pre-defined analysis of 8 RCTs (12-26 wks) & 3 open label studies up to 1 yr 2.5 * 1.95 11/563 2.0 1.5 Events/100 pt yrs) 0.68 8/1183 1.0 0.39 7/1791 0.5 0 0/146 0 Valdecoxib 5-80 mg (n=4362) Valdecoxib10-80 mg (n=2871) Placebo (n=973) NSAIDs(n=2099) Controlled Trials Open-Label * Significantly different from other treatments; p< 0.05 Goldstein et al. Alimentary Pharmacol Ther 2004;20:527-538

  6. Sources of CV Data for Valdecoxib • More limited CV safety database than celecoxib • Randomized controlled trials in arthritis • Short-term acute pain studies alone or in combination with parecoxib • No completed epidemiology studies – 3 ongoing

  7. Cardiovascular Safety of Valdecoxib: Meta-analysis • 19 randomized controlled trials and a total of 12,254 treated patients (>84% OA/RA) • 7,061 valdecoxib-treated patients • 2,235 placebo-treated patients • 2,958 patients treated with active comparators • Study duration: 2 wks – 12 months • 11 studies  3 month duration • Valdecoxib doses; 1 – 80 mg daily Valdecoxib exposure > 3 months – 2714 (50%) of patients > 6 months – 1176 (22%) of patients > 1 yr – 211 (4%) of patients

  8. CV Death, MI and Stroke:Valdecoxib vs NSAIDs n (events per 100 patient-years)

  9. CV Death, MI and Stroke:Valdecoxib vs NSAIDs Relative Risk (95%CI) 0.49 (0.21, 1.13) CV death, MI, or stroke 0.53 (0.13, 2.24) CV death 0.39 (0.11, 1.37) MI Stroke 0.43 (0.09, 2.05) 0.3 3.0 0.1 1.0 10.0 Favors NSAIDs Favors valdecoxib Valdecoxib daily dose > 10 mg

  10. Relative Risk (95%CI) vs. Placebo vs. NSAID vs. Naproxen vs. Diclofenac 0.38 (0.13, 1.09) vs. Ibuprofen No events 3.0 0.3 0.1 1.0 10.0 Favors comparator Favors valdecoxib CV Death, MI and Stroke:Valdecoxib vs Pbo, NSAIDs Combined & Individually 1.26 (0.35, 4.46) 0.49 (0.21, 1.13) 0.73 (0.18, 2.99) Valdecoxib daily dose > 10 mg

  11. CV Death, MI and Stroke:Valdecoxib vs NSAIDs: By Dose Relative Risk (95%CI) 0.49 (0.21, 1.13)  10 mg 0.27 (0.07, 1.04) 10 mg 0.38 (0.13, 1.17) 20 mg 1.36 (0.31, 5.94) 40 mg No events 80 mg 0.3 3.0 0.1 1.0 10.0 Favors NSAIDs Favors valdecoxib Valdecoxib daily dose > 10 mg

  12. Incidence of Cardiorenal Events n (percent of patients) NS = not significant (p>0.05) Combined analysis of RCTs

  13. Spontaneous reports of serious skin reactions received approximately 6 months after launch in the US Rate appears to be higher than celecoxib or rofecoxib Black Box warning added November 2004 Valdecoxib and Serious Skin Reactions

  14. Risk-Benefit of Valdecoxib in Arthritis - Conclusions • Efficacy similar to NSAIDs • Emerging data to establish: • GI safety benefit superior to NSAIDs • CV safety profile comparable to NSAIDs • Added warnings allow physicians to choose appropriately based on the evidence of rare although severe skin reactions.

  15. Future Plans for Valdecoxib • As with celecoxib, longer term studies are planned to evaluate the GI safety and CV safety of valdecoxib in arthritis patients.

  16. Parecoxib Sodium: Water Soluble Prodrug of Valdecoxib Parecoxib sodium Valdecoxib Water Solubility ~23 mg/ml ~0.08 mg/ml

  17. Medical Need for Parecoxib • Inadequate postoperative pain control is one of the most important factors in: • prolonging hospitalization • progression from acute pain to chronic pain • Postoperative analgesia traditionally provided by opioids • associated with complications (eg, ventilatory depression, nausea/vomiting, ileus) • inadequate analgesia upon movement • Multimodal analgesia (eg, drugs from 2 or more classes) • Earlier oral intake, ambulation, hospital discharge Parecoxib is intended to provide significant analgesia, sparing opioids without GI/bleeding risks of parenteral NSAIDs. White. Anesth Analg 2002;94:577-585

  18. Post-Operative Pain and Function Following Ambulatory Surgery Patients treated with Standard of Care Opioids Laparoscopy (n=59) 120 40 B Hernia (n=41) H 35 N=3729 100 H B 30 80 25 B 60 20 Functional Score Percent of Patients B 15 * 40 H * 10 H 20 B Mean + Std Dev p<0.05 vs pre * 5 H * * 0 0 None Mild Moderate Severe Pre-Surgery 1 day 4 days 7 days Time (post-surgery) Pain Status (day after surgery) Swan et al. Anesth Analg 1998;86:739-45 Chung et al. Anesth Analg 1997;85:808-16

  19. Background • Parecoxib was approved for short-term post-surgical pain in Europe March 2002 • > 1 million patients treated • Parecoxib NDA under review in US for management of acute pain

  20. Parecoxib Clinical Registration Program • 64 studies completed • 26 analgesia studies completed* • 10,086 patients randomized • 3,415 patients treated with placebo • 5,516 patients treated with parecoxib • 1,155 patients treated with active comparator** • 1,670 patients treated for >3 days with parecoxib • 1,183 patients treated for >10 days with parecoxib/valdecoxib * general surgery, oral and bunion surgery, renal colic trials ** morphine, ketorolac, ibuprofen, tramadol, valdecoxib

  21. Study DesignCABG Surgery Study 035 Day 3 Day 1 Day 14 Parecoxib 40 mg IV Q12h ® Valdecoxib 40 mg PO Q12h (N=311) Surgery* Extubate, baseline exam & labs; Randomize Placebo IV Q12h ® Placebo PO Q12h (N=151) Both treatment groups receive: PRN Supplemental Analgesia (PCA morphine à oral APAP+codeine) All patients received aspirin (80-325 mg daily) *89% cardiopulmonary bypass/11% off-pump cases

  22. Adjudicated Thromboembolic CV Events: CABG Surgery Study 035 * p<0.05 vs placebo; (n) percentage of patients with an event

  23. Study DesignCABG Surgery Study 071 Day 3 Day 1 Day 10 Parecoxib 40 mg IV loading dose + 20 mg IV Q12h ® Valdecoxib 20 mg PO Q12h (N=544) Surgery* Placebo IV Q12h ® Valdecoxib 20 mg PO Q12h (N=544) Randomize (Post-Op Day 1) Placebo IV Q12h ® Placebo PO Q12h (N=548) Both treatment groups receive: PRN Supplemental Analgesia (PCA morphine à oral APAP+codeine) All patients received aspirin (75-325 mg daily) *all cases were cardiopulmonary bypass

  24. Adjudicated Thromboembolic CV Events • Myocardial events: • MI, severe myocardial ischemia, • cardiac arrest, or sudden cardiac death • Cerebrovascular events: • Acute ischemic or hemorrhagic stroke, hemorrhagic infarction or TIA • Peripheral vascular events: • Vascular thrombosis (venous or arterial) • Pulmonary embolism

  25. Adjudicated Thromboembolic CV EventsCABG Surgery Study 071 Significantly different from placebo; p<0.05 -- p > 0.20 n (percent of patients)

  26. IV Study Medication Discontinued 3.0 ORAL 2.5 2.0 1.5 1.0 0.5 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 Adjudicated Thromboembolic CV EventsCABG Surgery Study 071 Time to Event Analysis Treatment Log rank test pbo/pbo vs pbo/valde, p=0.311 pbo/pbo vs pare/valde, p=0.030 Parecoxib/Valdecoxib (n=544) H H H Percent of Patients H H Valdecoxib only (n=544) J H J H J Placebo (n=548) J B H J B H J B H B J H Days

  27. Adjudicated Thromboembolic CV Events:CABG Surgery Study 071 * p<0.05 vs placebo; n (percentage of patients with an event)

  28. CABG Surgery • Limited data to evaluate the effects of NSAIDs in this setting • Mechanism for increased CV risk with parecoxib/ valdecoxib is not known: • CBP results in activation of platelets, leukocytes and endothelial cells • Aortic cross-clamping; ischemia reperfusion injury and emboli • Complex time course of changes in PGI2/TXA2 • High degree of platelet aspirin resistance These factors are largely confined to the CABG surgery setting Wan et al. Chest 1997;112:676-92Faymonville et al. J Thorac Cardiovasc Surg 1986;91:858-66Zimmerman et al. Circulation 2003;108:542-7

  29. Study DesignGeneral Surgery Study 069 Day 3 Day 1 Day 10 Parecoxib 40 mg IV loading dose + 20 mg IV/IM Q12h ® Valdecoxib 20 mg PO Q12h (N=525) Surgery Randomize (within 6 hr of surgery) Placebo IV Q12h ® Placebo PO Q12h (N=525) Both treatment groups receive: PRN Supplemental Analgesia (PCA morphine à oral APAP+codeine)

  30. Adjudicated Thromboembolic CV Events:General Surgery Study 069 n (percentage of patients with an event)

  31. ORAL Study Medication Discontinued 3.0 2.5 2.0 1.5 1.0 0.5 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 Adjudicated Thromboembolic CV EventsGeneral Surgery Study 069 Time to Event Analysis Treatment Log rank test placebo vs parecoxib/valdecoxib, p=0.999 IV/IM Placebo (N=525) B H Parecoxib/Valdecoxib (N=525) Percent of Patients B H B H B H B H B H H B Days

  32. Thromboembolic CV EventsCombined Parecoxib General Surgery Studies n (percentage of patients with an event)

  33. Daily Summed Pain Intensity Scoresa General Surgery Study 069 35 Placebo (n=525) Parecoxib / Valdecoxib (n=525) 30 25 * Mean Scorea 20 * * * 15 * * * 10 * * Less Pain 5 0 2 3 4 5 6 7 8 9 10 Days * Significantly different from placebo; p<0.05 a. Scale ranges from 0 to 72. Larger number indicates more pain

  34. p<0.001 -35%, p<0.001 0.6 75 0.59 66.2 0.39 0.4 50 43.2 Morphine Equivalents (mg) Morphine Equivalents (mg/hr) 0.2 25 p=0.085 0.11 0.08 0 0 IV Phase PO Phase Supplemental Opioid UseGeneral Surgery Study 069 Placebo (n=519) Parecoxib / Valdecoxib (n=520) Combined IV/PO

  35. Modified Brief Pain Inventory - Function:General Surgery Study 069 3.5 Placebo (N=525) 3.0 Parecoxib / Valdecoxib (N=525) 2.5 * 2.0 Mean Scorea 1.5 * * * 1.0 * * improved function * * * 0.5 0 2 3 4 5 6 7 8 9 10 Days * Significantly different from placebo; p<0.05 a. Scale ranges from 0 to 11. Larger number indicates greater interference with function Composite score: general activity, walking, sleeping, deep breathing, coughing, concentration, mood, relations with others

  36. Risk-Benefit of Parecoxib - Conclusions • Parecoxib offers unique benefits over existing parenteral analgesic medications and a favorable risk benefit ratio in surgical settings other than CABG/ revascularization • Parecoxib administered in controlled settings under physician observation • CV risk found only in CABG surgery setting; not observed in other surgical settings • other revascularization procedures not assessed

More Related